Fundraising FoxSofinnova Venture Partners — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)
Board seatAnand Mehra· per SEC Form D · $11.4M raise · filed Apr 2020
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Ventures+1 more
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.
BiotechDigital HealthMedical DevicesSouth San Francisco, US
Marshall Fordyce(Executive Officer, Director)in
BoardBeth Seidenberg(Director)inMaha Katabi(Director)inKurt von Emster(Director)inPatrick Enright(Director)inAndrew Cheng(Director)
Co-investorsKleiner PerkinsLongitude CapitalSofinnova VenturesAbingworth
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Iterum Therapeutics Bermuda
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.